Retatrutide vs Wegovy: Next-Gen vs Current Standard of Care

Retatrutide vs Wegovy is fundamentally a comparison between the current standard of care and its likely successor. Wegovy (semaglutide 2.4 mg) became the first truly effective pharmaceutical weight loss treatment, producing 15-17% average body weight loss with its single GLP-1 agonist mechanism. Now retatrutide, Eli Lilly's investigational triple agonist, has shown 24.2% average weight loss in Phase 2 trials (Jastreboff et al., NEJM 2023) — approaching bariatric surgery territory. What does this generational shift mean for patients?

Side-by-Side Comparison

Where Wegovy Still Wins

Despite retatrutide's superior weight loss numbers, Wegovy has important advantages that should not be overlooked:

• Available now: Wegovy has been on the market since 2021. Patients can start treatment immediately rather than waiting years for retatrutide's potential approval.
• Cardiovascular outcomes data: The SELECT trial demonstrated that semaglutide reduces major cardiovascular events by 20%, independent of weight loss. This is a proven cardiovascular benefit. Retatrutide has not yet completed its cardiovascular outcomes trial.
• Extensive real-world data: Millions of patients have used semaglutide (Wegovy/Ozempic), providing a vast body of real-world safety and efficacy data that Phase 2 trials cannot match.
• Well-established side effect profile: Physicians know exactly what to expect and how to manage Wegovy side effects. Retatrutide's Phase 3 safety profile is still being characterized.
• Insurance coverage: Many insurance plans now cover Wegovy. Retatrutide coverage negotiations have not begun.

Where Retatrutide Pulls Ahead

• Greater weight loss: 24.2% vs 15-17% is a clinically meaningful difference. For many patients, this could mean the difference between partial and full treatment success.
• Liver fat reduction: Retatrutide's 86% liver fat reduction dramatically outperforms Wegovy's more modest effects. For the 100 million Americans with fatty liver disease, this is potentially transformative.
• Energy expenditure: The glucagon component increases metabolic rate, fighting the metabolic adaptation that causes weight loss plateaus. Wegovy does not have this mechanism.
• Faster results: Greater weight loss in a shorter timeframe (48 weeks vs 68 weeks) means patients see meaningful changes sooner.
• Multiple comorbidity benefits: Dedicated trials for sleep apnea, osteoarthritis, and fatty liver suggest broad health benefits beyond weight loss.

Who Might Switch from Wegovy to Retatrutide?

When retatrutide becomes available, the strongest switch candidates would be:

• Patients who have plateaued on Wegovy short of their weight loss goal
• Patients with fatty liver disease needing greater liver fat reduction
• Patients with severe obesity (BMI 40+) who need maximum weight loss
• Patients who want to approach bariatric surgery-level results without surgery

Patients who are happy with their Wegovy results, who have achieved their goals, or who value Wegovy's proven cardiovascular benefits may prefer to stay on their current medication.

Start with Semaglutide Today

Semaglutide — the same active ingredient in Wegovy — is available now as a compounded formulation through TRIMI at a fraction of the brand-name cost:

• Compounded semaglutide: $99/month (vs ~$1,350/month for brand Wegovy)
• Compounded tirzepatide: $125/month — the dual-agonist option if you want more weight loss now

Starting treatment now means immediate health benefits while you wait for next-generation options. Learn more about how TRIMI works.